ReviewWorld journal of gastroenterology2014
Second and third line treatment options for Helicobacter pylori eradication.
Review in World journal of gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- First regional consensus on the management ofWorld journal of gastroenterology · 2025Guideline
- Fourth-generation quinolones in the treatment ofWorld journal of gastroenterology · 2018Pooled it
- The prolongation effect of ilaprazole-based standard triple therapy for Helicobacter pylori.Medicine · 2020Trial
- Bismuth adjuvant ameliorates adverse effects of high-dose chemotherapy in patients with multiple myeloma and malignant lymphoma undergoing autologous stem cell transplantation: a randomised, double-blind, prospective pilot study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2017Trial
- Comparison of Second-Line Quadruple Therapies with or without Bismuth for Helicobacter pylori Infection.BioMed research international · 2015Trial
- Rifabutin-based high-dose proton-pump inhibitor and amoxicillin triple regimen as the rescue treatment for Helicobacter pylori.Helicobacter · 2014Trial
- Low dose furazolidone for eradication of H- pylori instead of clarithromycin: a clinical trial.Global journal of health science · 2014Trial
- Synergistic potentiation of antibiotics by chamomile phytochemicals against multidrug-resistant Helicobacter pylori.Gut pathogens · 2025Article
- Design and Characterization of Novel Gastroretentive Drug Delivery System of Antibiotics and Piperine for the Eradication ofMolecular pharmaceutics · 2025Article
- Treatment ofHeliyon · 2023Review
- Unpacking the Racial Gap: Helicobacter pylori Infection Clearance Among Different Racial Groups.Cureus · 2023Article
- MAT Gain of Activity Mutation inACS infectious diseases · 2023Article
- Rifabutin for the Treatment ofPathogens (Basel, Switzerland) · 2020Review
- Alternative eradication regimens forInfection and drug resistance · 2019Article
- Therapeutic efficacy of amoxicillin and rifaximin in patients with small intestinal bacterial overgrowth andPrzeglad gastroenterologiczny · 2018Article
- Review article: the global emergence of Helicobacter pylori antibiotic resistance.Alimentary pharmacology & therapeutics · 2016Review
- Five-year sequential changes in secondary antibiotic resistance of Helicobacter pylori in Taiwan.World journal of gastroenterology · 2015Article
- Does emerging Clarithromycin resistance signal an obituary to empirical standard triple therapy for Helicobacter pylori infection?Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2015Article
- Efficacy of Clarithromycin Containing Bismuth-Based Regimen as a Second-Line Therapy in Helicobacter Pylori Eradication.Middle East journal of digestive diseases · 2015Article
- New Diagnostic Strategies for Detection of Helicobacter pylori Infection in Pediatric Patients.Gastroenterology & hepatology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Helicobacter pylori is a highly successful bacterium with a high global prevalence and the infection carries significant disease burden. It is also becoming increasingly difficult to eradicate and the main reason for this is growing primary antibiotic resistance rates in a world where antibiotics are frequently prescribed and readily available. Despite knowing much more about the bacterium since its discovery, such as its genomic makeup and pathogenesis, we have seen declining treatment success. Therefore, clinicians today must be prepared to face one, two or even multiple treatment failures, and should be equipped with sufficient knowledge to decide on the appropriate salvage therapy when this happens. This article discusses the factors contributing to treatment failure and reviews the second and third-line treatment strategies that have been investigated. Established empiric second line treatment options include both bismuth based quadruple therapy and levofloxacin based triple therapy. Antibiotic testing is recommended prior to initiating third line treatment. In the event that antibiotic susceptibility testing is unavailable, third line treatment options include rifabutin, rifaximin and sitafloxacin based therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.